Biotech developer Curis (CRIS +5%) gets a lift after saying it's entered into an agreement with...

|By:, SA News Editor

Biotech developer Curis (CRIS +5%) gets a lift after saying it's entered into an agreement with The Leukemia & Lymphoma Society to support the ongoing development of its oral small molecule dual Pi3K and HDAC inhibitor CUDC-907, a treatment for patients with B-cell lymphoma and multiple myeloma.